Search in:

Expert Opinion on Drug Metabolism & Toxicology Volume 5, 2009 - Issue 4

Submit an article Journal homepage

196

Views

107

CrossRef citations to date

Altmetric

Reviews

N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine

David W Hein University of Louisville School of Medicine, James Graham Brown Cancer Center, Center for Environmental Genomics and Integrative Biology, Department of Pharmacology & Toxicology, Louisville, KY 40292, USA +1 502 852 5141; +1 502 852 7868; [email protected]

Pages 353-366 | Published online: 21 Apr 2009

Cite this article
https://doi.org/10.1517/17425250902877698

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Weber WW. The acetylator genes and drug response. Oxford University Press, New York; 1987
Google Scholar
Weber WW, Hein DW. N-acetylation pharmacogenetics. Pharmacol Rev 1985;37:25-79
PubMed Web of Science ®Google Scholar
Boukouvala S, Fakis G. Arylamine N-acetyltransferases: what we learn from genes and genomes. Drug Metab Rev 2005;37:511-64
PubMed Web of Science ®Google Scholar
Westwood IM, Kawamura A, Fullam E, et al. Structure and mechanism of arylamine N-acetyltransferases. Curr Top Med Chem 2006;6:1641-54
PubMed Web of Science ®Google Scholar
Minchin RF, Hanna PE, Dupret JM, et al. Arylamine N-acetyltransferase I. Int J Biochem Cell Biol 2007;39:1999-2005
PubMed Web of Science ®Google Scholar
Sim E, Westwood I, Fullam E. Arylamine N-acetyltransferases. Expert Opin Drug Metab Toxicol 2007;3:169-84
PubMed Web of Science ®Google Scholar
Agundez JA. Polymorphisms of human N-acetyltransferases and cancer risk. Curr Drug Metab 2008;9:520-31
PubMed Web of Science ®Google Scholar
Grant DM. Structures of human arylamine N-acetyltransferases. Curr Drug Metab 2008;9:465-70
PubMed Web of Science ®Google Scholar
Sim E, Walters K, Boukouvala S. Arylamine N-acetyltransferases: from structure to function. Drug Metab Rev 2008;40:479-510
PubMed Web of Science ®Google Scholar
Sim E, Lack N, Wang CJ, et al. Arylamine N-acetyltransferases: structural and functional implications of polymorphisms. Toxicology 2008;254:170-83
PubMed Web of Science ®Google Scholar
Vatsis KP, Weber WW, Bell DA, et al. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995;5:1-17
PubMedGoogle Scholar
Hein DW, Boukouvala S, Grant DM, et al. Changes in consensus arylamine N-acetyltransferase gene nomenclature. Pharmacogenet Genomics 2008;18:367-8
PubMed Web of Science ®Google Scholar
Butcher NJ, Tiang J, Minchin RF. Regulation of arylamine N-acetyltransferases. Curr Drug Metab 2008;9:498-504
PubMed Web of Science ®Google Scholar
Badawi AF, Hirvonen A, Bell DA, et al. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Cancer Res 1995;55:5230-7
PubMed Web of Science ®Google Scholar
Bell DA, Badawi AF, Lang NP, et al. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res 1995;55:5226-9
PubMed Web of Science ®Google Scholar
Hein DW, McQueen CA, Grant DM, et al. Pharmacogenetics of the arylamine N-acetyltransferases: a symposium in honor of Wendell W Weber. Drug Metab Dispos 2000;28:1425-32
PubMed Web of Science ®Google Scholar
de Leon JH, Vatsis KP, Weber WW. Characterization of naturally occurring and recombinant human N-acetyltransferase variants encoded by NAT1. Mol Pharmacol 2000;58:288-99
PubMed Web of Science ®Google Scholar
Payton MA, Sim E. Genotyping human arylamine N-acetyltransferase type 1 (NAT1): the identification of two novel allelic variants. Biochem Pharmacol 1998;55:361-6
PubMed Web of Science ®Google Scholar
Bruhn C, Brockmoller J, Cascorbi I, et al. Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1). Biochem Pharmacol 1999;58:1759-64
PubMed Web of Science ®Google Scholar
Rodrigues-Lima F, Dairou J, Dupret JM. Effect of environmental substances on the activity of arylamine N-acetyltransferases. Curr Drug Metab 2008;9:505-9
PubMed Web of Science ®Google Scholar
Sinclair JC, Sandy J, Delgoda R, et al. Structure of arylamine N-acetyltransferase reveals a catalytic triad. Nat Struct Biol 2000;7:560-4
PubMedGoogle Scholar
Wu H, Dombrovsky L, Tempel W, et al. Structural basis of substrate-binding specificity of human arylamine N-acetyltransferases. J Biol Chem 2007;282:30189-97
PubMed Web of Science ®Google Scholar
Dupret JM, Grant DM. Site-directed mutagenesis of recombinant human arylamine N-acetyltransferase expressed in Escherichia coli. Evidence for direct involvement of Cys68 in the catalytic mechanism of polymorphic human NAT2. J Biol Chem 1992;267:7381-5
PubMed Web of Science ®Google Scholar
Goodfellow GH, Dupret JM, Grant DM. Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2. Biochem J 2000;348(Pt 1):159-66
PubMed Web of Science ®Google Scholar
Liu L, Von Vett A, Zhang N, et al. Arylamine N-acetyltransferases: characterization of the substrate specificities and molecular interactions of environmental arylamines with human NAT1 and NAT2. Chem Res Toxicol 2007;20:1300-8
PubMed Web of Science ®Google Scholar
Hein DW. Acetylator genotype and arylamine-induced carcinogenesis. Biochim Biophys Acta 1988;948:37-66
PubMed Web of Science ®Google Scholar
Walraven JM, Trent JO, Hein DW. Structure-function analyses of single nucleotide polymorphisms in human N-acetyltransferase 1. Drug Metab Rev 2008;40:169-84
PubMed Web of Science ®Google Scholar
Butcher NJ, Arulpragasam A, Minchin RF. Proteasomal degradation of N-acetyltransferase 1 is prevented by acetylation of the active site cysteine: a mechanism for the slow acetylator phenotype and substrate-dependent down-regulation. J Biol Chem 2004;279:22131-7
PubMed Web of Science ®Google Scholar
Fretland AJ, Doll MA, Leff MA, Hein DW. Functional characterization of nucleotide polymorphisms in the coding region of N-acetyltransferase 1. Pharmacogenetics 2001;11:511-20
PubMedGoogle Scholar
Fretland AJ, Doll MA, Zhu Y, et al. Effect of nucleotide substitutions in N-acetyltransferase-1 on N-acetylation (deactivation) and O-acetylation (activation) of arylamine carcinogens: implications for cancer predisposition. Cancer Detect Prev 2002;26:10-14
PubMedGoogle Scholar
Liu F, Zhang N, Zhou X, et al. Arylamine N-acetyltransferase aggregation and constitutive ubiquitylation. J Mol Biol 2006;361:482-92
PubMed Web of Science ®Google Scholar
Hughes NC, Janezic SA, McQueen KL, et al. Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe. Pharmacogenetics 1998;8:55-66
PubMedGoogle Scholar
Zhu Y, Hein DW. Functional effects of single nucleotide polymorphisms in the coding region of human N-acetyltransferase 1. Pharmacogenomics J 2008;8:339-48
PubMed Web of Science ®Google Scholar
Bruhn C, Brockmoller J, Cascorbi I, et al. Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1). Biochem Pharmacol 1999;58:1759-64
PubMed Web of Science ®Google Scholar
Zhangwei X, Jianming X, Qiao M, Xinhua X. N-Acetyltransferase-1 gene polymorphisms and correlation between genotype and its activity in a central Chinese Han population. Clin Chim Acta 2006;371:85-91
PubMed Web of Science ®Google Scholar
Doll MA, Jiang W, Deitz AC, et al. Identification of a novel allele at the human NAT1 acetyltransferase locus. Biochem Biophys Res Commun 1997;233:584-91
PubMed Web of Science ®Google Scholar
Walraven JM, Zang Y, Trent JO, Hein DW. Structure/function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2. Curr Drug Metab 2008;9:471-86
PubMed Web of Science ®Google Scholar
Hein DW, Ferguson RJ, Doll MA, et al. Molecular genetics of human polymorphic N-acetyltransferase: enzymatic analysis of 15 recombinant wild-type, mutant, and chimeric NAT2 allozymes. Hum Mol Genet 1994;3:729-34
PubMed Web of Science ®Google Scholar
Hein DW, Doll MA, Rustan TD, Ferguson RJ. Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions. Cancer Res 1995;55:3531-6
PubMed Web of Science ®Google Scholar
Fretland AJ, Leff MA, Doll MA, Hein DW. Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms. Pharmacogenetics 2001;11:207-15
PubMedGoogle Scholar
Zang Y, Doll MA, Zhao S, et al. Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2. Carcinogenesis 2007;28:1665-71
PubMed Web of Science ®Google Scholar
Zhu Y, Doll MA, Hein DW. Functional genomics of C190T single nucleotide polymorphism in human N-acetyltransferase 2. Biol Chem 2002;383:983-7
PubMed Web of Science ®Google Scholar
Zang Y, Zhao S, Doll MA, et al. The T341C (Ile114Thr) polymorphism of N-acetyltransferase 2 yields slow acetylator phenotype by enhanced protein degradation. Pharmacogenetics 2004;14:717-23
PubMedGoogle Scholar
Sandy J, Mushtaq A, Holton SJ, et al. Investigation of the catalytic triad of arylamine N-acetyltransferases: essential residues required for acetyl transfer to arylamines. Biochem J 2005;390:115-23
PubMed Web of Science ®Google Scholar
Zang Y, Zhao S, Doll MA, et al. Functional characterization of the A411T (L137F) and G364A (D122N) genetic polymorphisms in human N-acetyltransferase 2. Pharmacogenet Genomics 2007;17:37-45
PubMed Web of Science ®Google Scholar
Li SC, Goto NK, Williams KA, Deber CM. Alpha-helical, but not beta-sheet, propensity of proline is determined by peptide environment. Proc Natl Acad Sci USA 1996;93:6676-81
PubMed Web of Science ®Google Scholar
Walraven JM, Trent JO, Hein DW. Computational and experimental analyses of mammalian arylamine N-acetyltransferase structure and function. Drug Metab Dispos 2007;35:1001-7
PubMed Web of Science ®Google Scholar
Hein DW, Fretland AJ, Doll MA. Effects of single nucleotide polymorphisms in human N-acetyltransferase 2 on metabolic activation (O-acetylation) of heterocyclic amine carcinogens. Int J Cancer 2006;119:1208-11
PubMed Web of Science ®Google Scholar
Grant DM, Hughes NC, Janezic SA, et al. Human acetyltransferase polymorphisms. Mutat Res 1997;376:61-70
PubMed Web of Science ®Google Scholar
Hein DW. N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene 2006;25:1649-58
PubMed Web of Science ®Google Scholar
Grant DM, Blum M, Beer M, Meyer UA. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol 1991;39:184-91
PubMed Web of Science ®Google Scholar
Hein DW, Doll MA, Rustan TD, et al. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 1993;14:1633-8
PubMed Web of Science ®Google Scholar
Minchin RF, Reeves PT, Teitel CH, et al. N-and O-acetylation of aromatic and heterocyclic amine carcinogens by human monomorphic and polymorphic acetyltransferases expressed in COS-1 cells. Biochem Biophys Res Commun 1992;185:839-44
PubMed Web of Science ®Google Scholar
Hein DW, Rustan TD, Ferguson RJ, et al. Metabolic activation of aromatic and heterocyclic N-hydroxyarylamines by wild-type and mutant recombinant human NAT1 and NAT2 acetyltransferases. Arch Toxicol 1994;68:129-33
PubMed Web of Science ®Google Scholar
Lau EY, Felton JS, Lightstone FC. Insights into the o-acetylation reaction of hydroxylated heterocyclic amines by human arylamine N-acetyltransferases: a computational study. Chem Res Toxicol 2006;19:1182-90
PubMed Web of Science ®Google Scholar
Patin E, Harmant C, Kidd KK, et al. Sub-Saharan African coding sequence variation and haplotype diversity at the NAT2 gene. Hum Mutat 2006;27:720
PubMed Web of Science ®Google Scholar
Sabbagh A, Langaney A, Darlu P, et al. Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history. BMC Genet 2008;9:21
PubMed Web of Science ®Google Scholar
Husain A, Zhang X, Doll MA, et al. Functional analysis of the human N-acetyltransferase 1 major promoter: quantitation of tissue expression and identification of critical sequence elements. Drug Metab Dispos 2007;35:1649-56
PubMed Web of Science ®Google Scholar
Husain A, Zhang X, Doll MA, et al. Identification of N-acetyltransferase 2 (NAT2) transcription start sites and quantitation of NAT2-specific mRNA in human tissues. Drug Metab Dispos 2007;35:721-7
PubMed Web of Science ®Google Scholar
Yuliwulandari R, Sachrowardi Q, Nishida N, et al. Polymorphisms of promoter and coding regions of the arylamine N-acetyltransferase 2 (NAT2) gene in the Indonesian population: proposal for a new nomenclature. J Hum Genet 2008;53:201-9
PubMed Web of Science ®Google Scholar
Moslehi R, Chatterjee N, Church TR, et al. Cigarette smoking, N-acetyltransferase genes and the risk of advanced colorectal adenoma. Pharmacogenomics 2006;7:819-29
PubMed Web of Science ®Google Scholar
McKay JD, Hashibe M, Hung RJ, et al. Sequence variants of NAT1 and NAT2 and other xenometabolic genes and risk of lung and aerodigestive tract cancers in Central Europe. Cancer Epidemiol Biomarkers Prev 2008;17:141-7
PubMed Web of Science ®Google Scholar
Cartwright RA, Glashan RW, Rogers HJ, et al. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet 1982;2:842-5
PubMed Web of Science ®Google Scholar
Garcia-Closas M, Malats N, Silverman D, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 2005;366:649-59
PubMed Web of Science ®Google Scholar
Lang NP, Butler MA, Massengill J, et al. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidemiol Biomarkers Prev 1994;3:675-82
PubMed Web of Science ®Google Scholar
Chen J, Stampfer MJ, Hough HL, et al. A prospective study of N-acetyltransferase genotype, red meat intake, and risk of colorectal cancer. Cancer Res 1998;58:3307-11
PubMed Web of Science ®Google Scholar
Le Marchand L, Hankin JH, Wilkens LR, et al. Combined effects of well-done red meat, smoking, and rapid N-acetyltransferase 2 and CYP1A2 phenotypes in increasing colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2001;10:1259-66
PubMed Web of Science ®Google Scholar
Lilla C, Verla-Tebit E, Risch A, et al. Effect of NAT1 and NAT2 genetic polymorphisms on colorectal cancer risk associated with exposure to tobacco smoke and meat consumption. Cancer Epidemiol Biomarkers Prev 2006;15:99-107
PubMed Web of Science ®Google Scholar
Ognjanovic S, Yamamoto J, Maskarinec G, Le Marchand L. NAT2, meat consumption and colorectal cancer incidence: an ecological study among 27 countries. Cancer Causes Control 2006;17:1175-82
PubMed Web of Science ®Google Scholar
Cotterchio M, Boucher BA, Manno M, et al. Red meat intake, doneness, polymorphisms in genes that encode carcinogen-metabolizing enzymes, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2008;17:3098-107
PubMed Web of Science ®Google Scholar
Shin A, Shrubsole MJ, Rice JM, et al. Meat intake, heterocyclic amine exposure, and metabolizing enzyme polymorphisms in relation to colorectal polyp risk. Cancer Epidemiol Biomarkers Prev 2008;17:320-9
PubMed Web of Science ®Google Scholar
Goebel C, Hewitt NJ, Kunze G, et al. Skin metabolism of aminophenols: human keratinocytes as a suitable in vitro model to qualitatively predict the dermal transformation of 4-amino-2-hydroxytoluene in vivo. Toxicol Appl Pharmacol 2009;235:114-23
PubMed Web of Science ®Google Scholar
Hayes RB, Bi W, Rothman N, et al. N-acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers. Carcinogenesis 1993;14:675-8
PubMed Web of Science ®Google Scholar
Carreon T, Ruder AM, Schulte PA, et al. NAT2 slow acetylation and bladder cancer in workers exposed to benzidine. Int J Cancer 2006;118:161-8
PubMed Web of Science ®Google Scholar
Huang YS, Chern HD, Su WJ, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002;35:883-9
PubMed Web of Science ®Google Scholar
Cho HJ, Koh WJ, Ryu YJ, et al. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinb) 2007;87:551-6
PubMed Web of Science ®Google Scholar
Makarova SI. Human N-acetyltransferases and drug-induced hepatotoxicity. Curr Drug Metab 2008;9:538-45
PubMed Web of Science ®Google Scholar
Brockmoller J, Cascorbi I, Kerb R, Roots I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 1996;56:3915-25
PubMed Web of Science ®Google Scholar
Okkels H, Sigsgaard T, Wolf H, Autrup H. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiol Biomarkers Prev 1997;6:225-31
PubMed Web of Science ®Google Scholar
Filiadis IF, Georgiou I, Alamanos Y, et al. Genotypes of N-acetyltransferase-2 and risk of bladder cancer: a case-control study. J Urol 1999;161:1672-5
PubMed Web of Science ®Google Scholar
El Desoky ES, AbdelSalam YM, Salama RH, et al. NAT2*5/*5 genotype (341T>C) is a potential risk factor for schistosomiasis-associated bladder cancer in Egyptians. Ther Drug Monit 2005;27:297-304
PubMed Web of Science ®Google Scholar
van der Hel OL, Peeters PH, Hein DW, et al. NAT2 slow acetylation and GSTM1 null genotypes may increase postmenopausal breast cancer risk in long-term smoking women. Pharmacogenetics 2003;13:399-407
PubMedGoogle Scholar
Lubin JH, Kogevinas M, Silverman D, et al. Evidence for an intensity-dependent interaction of NAT2 acetylation genotype and cigarette smoking in the Spanish Bladder Cancer Study. Int J Epidemiol 2007;36:236-41
PubMed Web of Science ®Google Scholar
Garcia-Martin E. Interethnic and intraethnic variability of NAT2 single nucleotide polymorphisms. Curr Drug Metab 2008;9:487-97
PubMed Web of Science ®Google Scholar
Deitz AC, Rothman N, Rebbeck TR, et al. Impact of misclassification in genotype-exposure interaction studies: example of N-acetyltransferase 2 (NAT2), smoking, and bladder cancer. Cancer Epidemiol Biomarkers Prev 2004;13:1543-6
PubMed Web of Science ®Google Scholar
Agundez JA, Golka K, Martinez C, et al. Unraveling ambiguous NAT2 genotyping data. Clin Chem 2008;54:1390-4
PubMed Web of Science ®Google Scholar
Dairou J, Petit E, Ragunathan N, et al. Arylamine N-acetyltransferase activity in bronchial epithelial cells and its inhibition by cellular oxidants. Toxicol Appl Pharmacol 2009 [Epub ahead of print]
PubMedGoogle Scholar
Luca F, Bubba G, Basile M, et al. Multiple advantageous amino acid variants in the NAT2 gene in human populations. PLoS ONE 2008;3:e3136
Google Scholar
Matimba A, Del-Favero J, Van Broeckhoven C, Masimirembwa C. Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects. Hum Genomics 2009;3:169-90
PubMedGoogle Scholar
Hein DW. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res 2002;506-507:65-77
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date